ABIVAX is trading 4.22% up at €80.20; available evidence does not establish a catalyst for the October 14 move. - No clear company-specific announcement explaining the move appeared in available search results. - Recent company news concerns seven obefazimod abstracts scheduled for presentation at UEG Week, October 17–20, rather than a new event today. - The gain is opposite the provided biotech-sector and broad U.S. market direction, so neither clearly explains the rise.